.png){kind=logo}
2024 Board Elections
- Home
- About us
- Board of Directors
- 2024 Board Elections
We are pleased to announce the Slate of Nominees standing for election to the next Board of Directors including the following positions: Vice President (2024-2025), Treasurer (2024-2026) and two Director positions (2024-2026). We would like to thank all candidates willing to stand for election. On June 27 all ISDE members will receive an email containing a unique election ID link. Electors will simply click on the link to cast their anonymous votes. 2024 Board of Directors CandidatesVICE President (2024-2025)
Toho University Graduate School of Medicine Japan
Publications and editorial activities in the scientific field are shown below: A total of 560 publications, Total Citation=1329, h-index=59, i10-index=240 Editor & Associate editor: Cancer Science, Int J Clin Oncology, Ann Gastroenterological Surgery, Esophagus, Gastric Cancer, Ann Thoracic Cardiovascular Surgery, Journal of Hepato-Biliary-Pancreatic Sciences, Toho J Medicine Editorial Board: J Gastroenterology, Digestive Surgery, World J Gastroenterology, J Surgical Oncology, Dis Esophagus etc. Treasurer (2024-2026)
Amsterdam UMC The Netherlands
I currently serve on the board of the Dutch Society for Gastro-Intestinal Surgery (NVGIC), the European Society for Diseases of the Esophagus (ESDE), and the European Surgical Association (ESA). Additionally, I am the President of the Scientific Committee of the Dutch Upper GI Cancer Audit (DUCA) and a board member of the Dutch Green Operation Room. I am also the Program Chair of the EAES and a co-organizer of the 2025 ESDE and IGCC congresses in Amsterdam. Furthermore, I contribute to several other scientific and guideline committees and serve on the editorial boards of Digestive Surgery, Surgical Endoscopy, Cancers, and Artificial Intelligence Surgery. The ISDE is a very important society for me, uniting disciplines involved in the treatment of esophageal diseases worldwide. This multidisciplinary approach is of great significance. I have been an active member since 2013 and have attended all congresses since 2014. I have previously served on several ISDE committees, including the Research & Database Committee, the Esodata Membership Bylaws and Budget Subcommittee, the Membership Committee (Chair), and the Guidelines Committee. I am honored to serve as the Treasurer on the ISDE Board and am committed to advancing multidisciplinary and international collaboration for the benefit of the International Society for Diseases of the Esophagus. DIRECTORS (2024-2026) Zhigang Li Shanghai Chest Hospital China
I am an Associate Professor and Doctoral Supervisor at the Shanghai Jiao Tong University School of Medicine, as well as the Director of Thoracic Surgery and Esophageal Surgery at the Shanghai Chest Hospital. Since 2015, I have served as the Director of the Esophageal Surgery Program at Shanghai Chest Hospital, where I have successfully led the team in establishing the largest center for the treatment of complex esophageal diseases in China, where we have developed a comprehensive clinical treatment platform for esophageal diseases, including a robust diagnosis and treatment system for esophageal cancer, assisted by robot-assisted minimally invasive surgery, radiotherapy/immunotherapy, and unique technology for surgical treatment of GERD. Our center has gained recognition for its outstanding contributions in the fields of robot-assisted minimally invasive surgery and complex esophageal surgery, establishing itself as the largest esophageal surgery center in China and one of the world's leading centers in this field. I have extensive experience in the diagnosis, treatment, and management of esophageal cancer, focusing on robotic assisted minimally invasive surgery (RAMIE trial) and challenging esophageal surgeries. I am proud to have initiated the Neoadjuvant Immunotherapy for Esophageal Cancer (NICE) trial in China, which is one of the world's first registered clinical studies combining neoadjuvant chemotherapy and immunotherapy for esophageal cancer. Additionally, I led the completion of an international multi-center clinical trial, the preSINO study, which would have a significant impact on international guidelines for interpreting efficacy after neoadjuvant therapy for squamous cell oesophageal cancer. I am actively engaged in academic exchanges and educational training within the realm of esophageal surgery. I have developed an extensive training program, authored a clinical manual for esophageal cancer surgery, and established the nation's premier training center for robotic esophageal surgery. My foremost dedication lies in the advancement of esophageal cancer treatment by training more medical professionals within this discipline. I am honored to accept the role of Director of the ISDE Board. I am dedicated to facilitating international academic exchange and collaboration in the interest of The International Society for Diseases of the Esophagus. |
I am professor of the Department of Surgery and Clinical Oncology, at Toho University, Tokyo, Japan. My main clinical work is dedicated to esophageal and gastric cancer surgery. I'm in charge of the guidelines for the treatment of esophageal cancer and gastric cancer. My main research & scientific interests are immunotherapy and biomarkers to improve the overall prognosis of cancer patients. I have been a board member and a chief of the international committee of JES. I was the president of the Annual Congress of Japan Esophageal Society in 2022. I have been a board member and program committee of ISDE. I am very pleased and honored to be given the opportunity to take charge of vice president at the ISDE Board. I also want to take full advantage of the opportunities to work to develop international cooperation for the benefit of ISDE and its members.
Affiliated Societies
|
|
International Interdisciplinary Everything Esophageal
|
